{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:27:00Z","timestamp":1793158020353,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"DOI":"10.7759\/cureus.77781","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:03:56Z","timestamp":1737475436000},"source":"Crossref","is-referenced-by-count":5,"title":["The Role of PET Detection of Biomarkers in Early Diagnosis, Progression, and Prognosis of Alzheimer\u2019s Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Viktoriia","family":"Zarovniaeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summayya","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cortez Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehej","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane CA","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018, 25:59-70. 10.1111\/ene.13439","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","author":"Alzheimer's Association","year":"2024","unstructured":"Alzheimer's Association. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024, 20:3708-821. 10.1002\/alz.13809","journal-title":"Alzheimers Dement"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30053-X","article-title":"The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study","volume":"17","author":"van der Lee SJ","year":"2018","unstructured":"van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, van Duijn CM. The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study. Lancet Neurol. 2018, 17:434-44. 10.1016\/S1474-4422(18)30053-X","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens P","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, et al.. Alzheimer's disease. Lancet. 2021, 397:1577-90. 10.1016\/S0140-6736(20)32205-4","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman AM","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS, et al.. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021, 17:1353-64. 10.1002\/alz.12301","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S135561771700100X","article-title":"Alzheimer's disease: past, present, and future","volume":"23","author":"Bondi MW","year":"2017","unstructured":"Bondi MW, Edmonds EC, Salmon DP. Alzheimer's disease: past, present, and future. J Int Neuropsychol Soc. 2017, 23:818-31. 10.1017\/S135561771700100X","journal-title":"J Int Neuropsychol Soc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Alzheimer's disease","volume":"167","author":"Soria Lopez JA","year":"2019","unstructured":"Soria Lopez JA, Gonz\u00e1lez HM, L\u00e9ger GC. Alzheimer's disease. Handb Clin Neurol. 2019, 167:231-55. 10.1016\/B978-0-12-804766-8.00013-3","journal-title":"Handb Clin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al.. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018, 14:535-62. 10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170680","article-title":"Cerebrospinal fluid biomarkers for early and differential Alzheimer\u2019s disease diagnosis","volume":"62","author":"Bjerke M","year":"2018","unstructured":"Bjerke M, Engelborghs S. Cerebrospinal fluid biomarkers for early and differential Alzheimer\u2019s disease diagnosis. J Alzheimers Dis. 2018, 62:1199-209. 10.3233\/JAD-170680","journal-title":"J Alzheimers Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042110","article-title":"Imaging techniques in Alzheimer\u2019s disease: a review of applications in early diagnosis and longitudinal monitoring","volume":"22","author":"van Oostveen WM","year":"2021","unstructured":"van Oostveen WM, de Lange EC. Imaging techniques in Alzheimer\u2019s disease: a review of applications in early diagnosis and longitudinal monitoring. Int J Mol Sci. 2021, 22:2110. 10.3390\/ijms22042110","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06603-2","article-title":"The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer's disease","volume":"51","author":"G\u00e9rard T","year":"2024","unstructured":"G\u00e9rard T, Colmant L, Malotaux V, et al.. The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2024, 51:1662-74. 10.1007\/s00259-024-06603-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00807-6","article-title":"Early detection of amyloid load using 18F-florbetaben PET","volume":"13","author":"Bullich S","year":"2021","unstructured":"Bullich S, Ro\u00e9-Vellv\u00e9 N, Marqui\u00e9 M, et al.. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021, 13:67. 10.1186\/s13195-021-00807-6","journal-title":"Alzheimers Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240349","article-title":"Positron emission tomography\/computed tomography imaging in therapeutic clinical trials in Alzheimer\u2019s disease: an overview of the current state of the art of research","volume":"101","author":"Triumbari EK","year":"2024","unstructured":"Triumbari EK, Chiaravalloti A, Schillaci O, Mercuri NB, Liguori C. Positron emission tomography\/computed tomography imaging in therapeutic clinical trials in Alzheimer\u2019s disease: an overview of the current state of the art of research. J Alzheimers Dis. 2024, 101:S603-28. 10.3233\/JAD-240349","journal-title":"J Alzheimers Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12069","article-title":"Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study","volume":"16","author":"Lopes Alves I","year":"2020","unstructured":"Lopes Alves I, Collij LE, Altomare D, et al.. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020, 16:750-8. 10.1002\/alz.12069","journal-title":"Alzheimers Dement"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51195","article-title":"Amyloid-\u03b2 PET and CSF in an autopsy-confirmed cohort","volume":"7","author":"Reimand J","year":"2020","unstructured":"Reimand J, Boon BD, Collij LE, et al.. Amyloid-\u03b2 PET and CSF in an autopsy-confirmed cohort. Ann Clin Transl Neurol. 2020, 7:2150-60. 10.1002\/acn3.51195","journal-title":"Ann Clin Transl Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16049","article-title":"Anti-amyloid antibody treatments for Alzheimer's disease","volume":"31","author":"Perneczky R","year":"2024","unstructured":"Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti-amyloid antibody treatments for Alzheimer's disease. Eur J Neurol. 2024, 31:e16049. 10.1111\/ene.16049","journal-title":"Eur J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.23","article-title":"Diagnosis of early Alzheimer's disease: clinical practice in 2021","volume":"8","author":"Porsteinsson AP","year":"2021","unstructured":"Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer's disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021, 8:371-86. 10.14283\/jpad.2021.23","journal-title":"J Prev Alzheimers Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","unstructured":"Joanna Briggs Institute. Critical appraisal tools. (2021). https.\/\/jbi.global\/critical-appraisal-tools."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-023-00897-0","article-title":"Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of 18F-FDG-PET","volume":"46","author":"Zhang Q","year":"2024","unstructured":"Zhang Q, Fan C, Wang L, Li T, Wang M, Han Y, Jiang J. Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of 18F-FDG-PET. Geroscience. 2024, 46:1407-20. 10.1007\/s11357-023-00897-0","journal-title":"Geroscience"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01351-1","article-title":"Clinical outcomes up to 9\u00a0years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population","volume":"15","author":"Collij LE","year":"2023","unstructured":"Collij LE, Farrar G, Zwan M, et al.. Clinical outcomes up to 9\u00a0years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population. Alzheimers Res Ther. 2023, 15:207. 10.1186\/s13195-023-01351-1","journal-title":"Alzheimers Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102713","article-title":"Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories","volume":"31","author":"Ackley SF","year":"2021","unstructured":"Ackley SF, Hayes-Larson E, Brenowitz WD, et al.. Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories. Neuroimage Clin. 2021, 31:102713. 10.1016\/j.nicl.2021.102713","journal-title":"Neuroimage Clin"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051282","article-title":"Clinical relevance of [18F]florbetaben and [18F]FDG PET\/CT imaging on the management of patients with dementia","volume":"26","author":"Librizzi D","year":"2021","unstructured":"Librizzi D, Cabanel N, Zavorotnyy M, Riehl E, Kircher T, Luster M, Hooshyar Yousefi B. Clinical relevance of [18F]florbetaben and [18F]FDG PET\/CT imaging on the management of patients with dementia. Molecules. 2021, 26:1282. 10.3390\/molecules26051282","journal-title":"Molecules"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"La Joie R","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, et al.. Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020, 12:eaau5732. 10.1126\/scitranslmed.aau5732","journal-title":"Sci Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101823","article-title":"Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease","volume":"23","author":"Sintini I","year":"2019","unstructured":"Sintini I, Martin PR, Graff-Radford J, et al.. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. Neuroimage Clin. 2019, 23:101823. 10.1016\/j.nicl.2019.101823","journal-title":"Neuroimage Clin"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2022.63.3.259","article-title":"18F-THK5351 PET positivity and longitudinal changes in cognitive function in \u03b2-amyloid-negative amnestic mild cognitive impairment","volume":"63","author":"Chun MY","year":"2022","unstructured":"Chun MY, Lee J, Jeong JH, et al.. 18F-THK5351 PET positivity and longitudinal changes in cognitive function in \u03b2-amyloid-negative amnestic mild cognitive impairment. Yonsei Med J. 2022, 63:259-64. 10.3349\/ymj.2022.63.3.259","journal-title":"Yonsei Med J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071460","article-title":"Exploratory tau PET\/CT with [11C]PBB3 in patients with suspected Alzheimer\u2019s disease and frontotemporal lobar degeneration: a pilot study on correlation with PET imaging and cerebrospinal fluid biomarkers","volume":"12","author":"Strobel J","year":"2024","unstructured":"Strobel J, Yousefzadeh-Nowshahr E, Deininger K, et al.. Exploratory tau PET\/CT with [11C]PBB3 in patients with suspected Alzheimer\u2019s disease and frontotemporal lobar degeneration: a pilot study on correlation with PET imaging and cerebrospinal fluid biomarkers. Biomedicines. 2024, 12:1460. 10.3390\/biomedicines12071460","journal-title":"Biomedicines"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220294","article-title":"Amyloid-PET levels in the precuneus and posterior cingulate cortices are associated with executive function scores in preclinical Alzheimer\u2019s disease prior to overt global amyloid positivity","volume":"88","author":"Ali DG","year":"2022","unstructured":"Ali DG, Bahrani AA, Barber JM, et al.. Amyloid-PET levels in the precuneus and posterior cingulate cortices are associated with executive function scores in preclinical Alzheimer\u2019s disease prior to overt global amyloid positivity. J Alzheimers Dis. 2022, 88:1127-35. 10.3233\/JAD-220294","journal-title":"J Alzheimers Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103457","article-title":"Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer's disease","volume":"39","author":"O'Dell RS","year":"2023","unstructured":"O'Dell RS, Higgins-Chen A, Gupta D, et al.. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer's disease. Neuroimage Clin. 2023, 39:103457. 10.1016\/j.nicl.2023.103457","journal-title":"Neuroimage Clin"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00742-y","article-title":"Association of A\u03b2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J","volume":"13","author":"O'Dell RS","year":"2021","unstructured":"O'Dell RS, Mecca AP, Chen MK, et al.. Association of A\u03b2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. Alzheimers Res Ther. 2021, 13:11. 10.1186\/s13195-020-00742-y","journal-title":"Alzheimers Res Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/323303-the-role-of-pet-detection-of-biomarkers-in-early-diagnosis-progression-and-prognosis-of-alzheimers-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:04:01Z","timestamp":1737475441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/323303-the-role-of-pet-detection-of-biomarkers-in-early-diagnosis-progression-and-prognosis-of-alzheimers-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.77781","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,21]]}}}